Nick Vatakis
New York, NYNPI 1285835637
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$5,585,158in research payments, 2019–2025
Across 554 payments — averaging $10,082 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.1M
- Sage Therapeutics, LLC$966K
- Axsome Therapeutics, Inc.$578K
- Pfizer$488K
- Imbrium Therapeutics L.p.$454K
- Janssen Research & Development, LLC$409K
- plus $1.6M from 13 others
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 21 | $32,687 |
| KlonopinClonazepam | 20 | $3,689 |
| Lamotrigine ErLamotrigine | 12 | $2,301 |
| Bupropion XlBupropion Hcl | 27 | $939 |
| Lamotrigine | 28 | $845 |
| Clonazepam | 68 | $811 |
| Lurasidone Hcl | 21 | $782 |
| Bupropion Hcl SrBupropion Hcl | 12 | $580 |
| Escitalopram Oxalate | 19 | $379 |
| Trazodone Hcl | 41 | $315 |
| Duloxetine Hcl | 21 | $277 |
| Zolpidem Tartrate | 49 | $261 |
| Lorazepam | 36 | $231 |
| Sertraline Hcl | 24 | $169 |
| Gabapentin | 17 | $165 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.